Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Abstract The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso‐cel in Japanese patients with relapsed or refractory (R/R) ag...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2022-12-01
Col·lecció:	Cancer Medicine
Matèries:	Japanese patients large B‐cell lymphoma lisocabtagene maraleucel non‐Hodgkin lymphoma relapsed/refractory
Accés en línia:	https://doi.org/10.1002/cam4.4820
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!